Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1985-03-06
1987-04-14
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514912, A61K 3119
Patent
active
046579303
ABSTRACT:
Disclosed are mitotic inhibitors effective for and methods of preventing posterior lens capsule opacification after extracapsular extraction. The mitotic inhibitors comprise osmotically balanced solutions containing either methotrexate or retinoic acid, or both, in at least the minimal effective dosage at the end of one lens epithelial cell cycle. The mitotic inhibitors are instilled in the anterior chamber of the eye preferably immediately after the lens has been removed.
REFERENCES:
patent: 3089823 (1963-05-01), Czarnecki
Dispersa--Therapeutic Index--re: Vitamin A.
ARVO-1984-Invest. Ophth. & Vis. Sci. 25 (3)(1984)--Ubels et al.--Vitamin A is Present as Retinol in Tears.
Chem. Abst. 99:47928t (1983)--Chan et al.
Chem. Abst. 99:47929n (1983)--Baylor College of Med.
Chan Raymond Y.
Emery Jared M.
Baylor College of Medicine
Robinson Douglas W.
LandOfFree
Mitotic inhibitors preventing posterior lens capsule opacificati does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mitotic inhibitors preventing posterior lens capsule opacificati, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mitotic inhibitors preventing posterior lens capsule opacificati will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1786043